Outsourcing partner to companies in the pharma, medical device and clinical trials industries, Wasdell Group, has revealed it is investing £500k in a new laboratory at its Newcastle site.
Investment
This investment has been driven by the company’s continuously growing customer base at its manufacturing facility in Newcastle as well as an increase in the number of pre-clinical development projects that have recently been awarded to the group.
The new lab will be 1,200 sq ft in size and will allow Wasdell to offer in-house microbiological and analytical services to its customers. Additionally, it will support the company’s manufacturing, packaging and quality control (QC) teams.
“This latest investment is part of a client-centric strategy that ensures we continue to offer existing and new clients a fast and efficient service that meets their end-to-end supply needs,” stated Daniel Tedham, managing director at Wasdell. “We’ve seen a notable increase in demand for analytical support from our existing clients and the investment in our microbiological capabilities has been driven by our planned move into the manufacture of sterile products later this year.”
Additionally, the lab will offer analytical capabilities for chemical, physical and microbiological analysis including HPLC, FTIR and wet chemistry with QC testing of raw materials, drug substances (currently Schedule III with capacity to cater for Schedule II products) and drug products in accordance with phamacopoeial monographs and client methods.
Tedham continued: “The new lab opens the door for further investment in the Newcastle facility, expansion of our on-site QC capabilities and future opportunities for growth to meet our client requirements.”